Lucid Capital initiated coverage of Atai Life Sciences (ATAI) with a Buy rating and $12 price target Atai has assembled one of the largest drug portfolios in “seven short years,” including four psychedelic programs, to revolutionize the treatment of mental health, the analyst tells investors in a research note. The firm views the company as an “aspiring leader” in mental health.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATAI:
- ATAI Life Sciences and Beckley Psytech Merger: Strategic Moves and Promising Pipeline Justify Buy Rating
- Psychedelic: atai, Beckly Psytech to combine in all-share transaction
- Strategic Acquisition and Promising Data Boost ATAI Life Sciences’ Buy Rating
- Strategic Merger and Financial Strength Propel ATAI Life Sciences to ‘Buy’ Rating
- ATAI Life Sciences Announces Share Purchase Agreement